This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
With only one out of every three patients using antidepressants achieve remission, its no secret why more and more patients suffering from depression seek TMS treatment. Jersey Matters interviews a BrainsWay Deep TMS patient, who describes his excitement and motivation to pursue his gardening hobby, post dTMS treatment.